We are live on ! Find out more

Eli Lilly

LLY

Market cap $1.01T

1,137.45 USD

-12.40

1.08%

At close Updated Oct 2, 12:13 PM EDT

1 day

-1.08%

5 days

-3.63%

1 month

-1.95%

3 months

-6.3%

6 months

21.58%

Year to date

5.28%

1 year

38.74%

5 years

405.87%

10 years

1,304.26%

About: Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Employees: 50,000

Healthcare Drug Manufacturers - General

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 56.6%

Neutral 31.3%

Negative 12.1%

24/7 Wall Street

Prediction: Eli Lilly Could Be the Next $2 Trillion Drugmaker

Eli Lilly just posted a 47.7% revenue surge while rivals like Novo Nordisk are watching earnings fall, and a fresh pipeline catalyst could push Lilly toward a valuation Wall Street has only seen from two companies in history.

Prediction: Eli Lilly Could Be the Next $2 Trillion Drugmaker

Proactive Investors

Eli Lilly obesity drug data adds pressure on Novo Nordisk

Novo Nordisk (NYSE:NVO) faces further pressure in the obesity-drug market after Eli Lilly and Co (NYSE:LLY) reported promising mid-stage data for an experimental treatment that delivered greater weight loss than tirzepatide alone. EloraTZP, a combination of eloralintide and tirzepatide targeting amylin, glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 pathways, produced weight loss of up to 23.3% after 48 weeks in overweight or obese patients with type 2 diabetes.

Eli Lilly obesity drug data adds pressure on Novo Nordisk

The Motley Fool

Johnson & Johnson vs. Eli Lilly: Which Pharma Stock Can Make Your Portfolio Healthier in 2026?

Johnson & Johnson maintains a diversified healthcare footprint across pharmaceutical innovation and medical technology. Eli Lilly continues to see exceptional top-line expansion driven by its leadership in the obesity and diabetes treatment markets.

Johnson & Johnson vs. Eli Lilly: Which Pharma Stock Can Make Your Portfolio Healthier in 2026?

The Motley Fool

Could Eli Lilly's Newest Weight Loss Strategy Pay Off for Decades?

Eli Lilly is looking to increase global access to weight loss and diabetes drugs. There is a large opportunity to exploit, given the prevalence of these conditions in low-income countries.

Could Eli Lilly's Newest Weight Loss Strategy Pay Off for Decades?

Trump Medicare drug pricing model may apply to only four companies after exemptions

A Trump administration rule to cut hospital drug prices for Medicare patients may apply to as few as four drugmakers after exempting ‌companies that signed separate "most favored nation" pricing agreements with the administration, according to the finalized rule.

Trump Medicare drug pricing model may apply to only four companies after exemptions

Zacks Investment Research

Will Lilly (LLY) Beat Estimates Again in Its Next Earnings Report?

Lilly (LLY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Lilly (LLY) Beat Estimates Again in Its Next Earnings Report?

Foghorn Therapeutics Pivots Pipeline after Ending Eli Lilly Deal

Foghorn Therapeutics Inc. (NASDAQ:FHTX) stock is trading lower on Thursday with a session volume of 9.158 million, compared to the average volume of 377.206 thousand, as per Benzinga Pro data.

Foghorn Therapeutics Pivots Pipeline after Ending Eli Lilly Deal

Zacks Investment Research

Novo's Wegovy Pill Shows Weight Loss After Switching From Injections

NVO's Wegovy pill delivers an average weight loss of 4.1% after three months for adults switching from injectable GLP-1 therapies.

Novo's Wegovy Pill Shows Weight Loss After Switching From Injections

Zacks Investment Research

Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to Win

LLY and Novo face off at EASD as new data fuels the GLP-1 market, while ETFs offer diversified exposure to weight loss drug growth.

Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to Win

Top 25 High-Growth Dividend Stocks For October 2026

The October 2026 Top 25 High-Growth Dividend Stocks list targets quality companies trading 31% below intrinsic value, with a projected 22.53% annual return. The list's average starting dividend yield is 1.51%, and the companies have grown dividends at 18.81% annually over five years. Stocks are categorized into Deep Value, Growth At A Price, and Balanced Opportunities, supporting diverse investment strategies based on valuation and growth.

Top 25 High-Growth Dividend Stocks For October 2026

See News Rankings

Price charts implemented using Lightweight Charts™